THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 6, 2006--Amgen
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced that it plans to report its second quarter financial results
on Thursday, July 20, 2006 after the close of the financial markets.
The announcement will be followed by a conference call with the
investment community at 2 p.m. Pacific Daylight Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, and other members of Amgen´s
senior management team.
Live audio of the conference call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public. The conference call, including the
question and answer session, is expected to last approximately one
The webcast of the conference, as with other selected
presentations regarding developments in Amgen´s business given by
management at certain investor and medical conferences, can be found
on Amgen´s Web site, www.amgen.com, under Investors. Information
regarding presentation times, webcast availability, and webcast links
are noted on Amgen´s Investor Relations Events Calendar. The webcast
will be archived and available for replay 72 hours after the event.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Dan Whelan, 805-447-5995 (media)
Arvind Sood, 805-447-1060 (investors)